Contribute to advancing knowledge

The advances we’ve made to date, as well as our future scientific discoveries, depend on our ability to partner with individuals with early psychosis or clinical high-risk symptoms and their families in our research.    

 

Why participate in research?

Here are 5 reasons.

1. Advance knowledge: You’ll contribute to the advancement of research about early psychosis and its treatment.

 

2. Understand worrisome experiences: You’ll receive a detailed clinical interview with results to help you understand worrisome experiences you may be experiencing. With your permission, these results can also be shared with your family or clinician to optimize your treatment.

 

3. Get a picture of your brain: Some studies include a brain MRI scan, so we can provide you with a picture of your brain.  If we see something unusual (which is rare), we will consult with a neuroradiologist and share results with you. 

 

4. You'll be paid. You’ll get compensated for your research participation.

 

5. It's free. Any assessments or treatments you receive are free of charge.

 

Our ongoing studies, including clinical treatment trials, are open to eligible individuals regardless of health insurance status.   
 


 

Studies that are actively recruiting

Understanding Prodromes and Lessening Illness in Family Therapy (UPLIFT)

UCSF Path Program joins UPLIFT, a family treatment study for teens and young adults (ages 13-25 years) showing early symptoms indicating risk for psychosis. The Path Program is collaborating with seven university-based early psychosis clinics in North America to make advances in family-focused treatments for young people at clinical high risk for psychosis.

This study tests the idea that effective prevention and treatment involves working with the whole family, not just the person affected. Through mental health education, communication enhancement training, and problem-solving skills training, the treatment program aims to prevent young people from developing more severe forms of psychosis and to improve their functioning.

 

 

Psychosis Risk Outcomes Network (ProNET)

UCSF Path Program joins the National Institutes of Mental Health’s (NIMH) Accelerating Medicines Partnership® (AMP®)* focused on the development of promising therapies for those at risk of developing psychosis, including schizophrenia (SCZ).

The AMP-SCZ public-private partnership brings together NIMH, US Food and Drug Administration, pharmaceutical companies, non-profit organizations, and two networks of university-based clinical research programs across the world, to discover better ways to identify and treat young people at clinical high risk for psychosis. UCSF is one of 26 participating U.S.-based ProNET sites.  

 

 

 

* ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services.